BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
수요일, 9월 30

Larimar Therapeutics Inc

LRMRNASDAQ
Trade with Public
Trade with Public
$3.14
마지막 업데이트: Sep 30, 9:30 AM
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교주식 보고서

Larimar Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Larimar Therapeutics (LRMR).

Price Target Range — 12 Quarters

Analyst Consensus — 11 Analysts

1S.Buy
10Buy
Consensus RatingBuy# Analysts11Avg. Consensus PT$15Upside to Avg. PT+389.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Sep 14, 2026Leerink PartnersJoseph SchwartzAssumesOutperform$13
Aug 5, 2026WedbushLaura ChicoPT CutOutperform$12→$11
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $11

Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $12 to $11.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Assumes Larimar Therapeutics at Buy, Announces Price Target of $10

HC Wainwright & Co. analyst Raghuram Selvaraju assumes Larimar Therapeutics (NASDAQ:LRMR) with a Buy rating and announces Price Target of $10.
Benzinga Newsdesk

PRO
Baird Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $5

Baird analyst Joel Beatty maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $7 to $5.
Benzinga Newsdesk

PRO
JP Morgan Initiates Coverage On Larimar Therapeutics with Overweight Rating, Announces Price Target of $9

JP Morgan analyst Tessa Romero initiates coverage on Larimar Therapeutics (NASDAQ:LRMR) with a Overweight rating and announces Price Target of $9.
Benzinga Newsdesk

Nvidia To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Monday

Top analysts changed outlook on top names. Keybanc, Leerink, Wedbush, DA Davidson, Benchmark, Piper Sandler, Morgan Stanley, Evercore raised price targets.
Avi Kapoor

PRO
Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $12

Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $13 to $12.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved